Biogen
NEWS
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
The license and collaboration agreement center on orelabrutinib, an oral small molecule BTKi characterized by its high selectivity and the ability to cross the blood-brain barrier.
Adulhelm’s proposed price tag of $56,000 per patient per year is hardly the most expensive drug on the market, but controversy regarding packaging and pricing continues.
Acting commissioner of the U.S. FDA asked the independent Office of the Inspector General to investigate how the FDA and representatives of Biogen interacted prior to the FDA’s approval of the company’s Aduhelm (aducanumab) for Alzheimer’s disease.
The saga continues for Biogen’s Alzheimer’s drug Aduhelm as the U.S. Food and Drug Administration approved an updated label that emphasizes the disease stages for which the drug was approved.
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.
The House Committee on Oversight and Reform announced plans to investigate the approval and pricing of the drug. Biogen, on its part, has defended its pricing.
The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.
JOBS
IN THE PRESS